CSPC and AstraZeneca Joint Venture: A New Logic for MNCs to “Build Factories” in China
A British pharmaceutical giant has decided to build its most advanced production line in Shijiazhuang, a second-tier city on the North China Plain.
On August 5, AstraZeneca and CSPC Pharmaceutical Group (or CSPC) signed an agreement to establish a joint venture to build a new generation of biopharmaceutical production base in Shijiazhuang, in order to further deepen their strategic cooperation.
The news wasn’t sudden. On the same day, CSPC announced it had received a $10 million milestone payment from AstraZeneca—a result of an AI-driven drug development agreement signed between the two companies in 2025. Following this, a deeper, more complex contract was brought to the forefront.
This is far from a simple licensing transaction. It’s a joint venture. CSPC holds 51% of the shares, and AstraZeneca holds 49%.
From “selling products” to “selling technology,” and then to “building factories together,” the relationship between CSPC and AstraZeneca has undergone a three-stage leap in less than two years. Behind this relationship lies a profound transformation taking place in the entire Chinese pharmaceutical industry: multinational pharmaceutical companies no longer see China merely as a sales market, and Chinese pharmaceutical companies are no longer content with simply being contract manufacturers.
It’s not just about building a factory.
The specific details of this cooperation agreement do not appear to be complicated.
The joint venture established by CSPC and AstraZeneca will initially focus on producing and supplying biologic drug substances (DS) agreed upon by both parties to the global market. In the future, depending on capacity expansion and commercial demand, the product line may be further expanded.
However, there are several points worth exploring beneath the surface of this agreement.
The first point of interest: Who is in charge?
CSPC holds a 51% stake to 49%, a significant controlling stake. This is unusual for a top-tier global pharmaceutical company. Typically, in joint ventures established by multinational corporations (MNCs) in China, foreign investors tend to hold a controlling stake or at least an equal share. In this instance, AstraZeneca accepted a minority shareholder role.
This means that AstraZeneca recognizes CSPC’s capabilities in production and operations, and is even willing to integrate its global supply chain into a factory led by CSPC.
In its announcement, CSPC stated that this collaboration “fully demonstrates the high recognition of its modern production system, quality management capabilities, and industrialization execution capabilities by a leading global multinational pharmaceutical company.” Entrusting a MNC with its production capacity to your factory is itself a highly valuable vote of trust.
The second highlight: AI-driven GMP.
A key phrase in the joint venture’s positioning is “AI-driven GMP production operations.” Shijiazhuang Pharmaceutical Group’s investment in intelligent manufacturing in recent years is becoming one of its core assets in attracting international partners.
Traditional GMP relies on human-to-human process management, while AI-driven GMP signifies that numerous processes, from production scheduling to quality control, can be optimized and monitored in real time by algorithms. This capability is precisely the “next-generation manufacturing capability” that AstraZeneca is seeking in its global supply chain strategy.
The third point of interest: globalized production and supply.
The joint venture’s products are not only intended for the Chinese market, but are “produced and supplied to the global market.” This means that the biopharmaceuticals produced at the Shijiazhuang factory will directly enter AstraZeneca’s global supply chain. China is not only AstraZeneca’s sales market and R&D base, but is also becoming one of its global manufacturing hubs.
The fourth point to note: This is just the beginning.
The agreement also revealed that, with the development of business, expansion of production capacity and growth in commercial demand, the two parties will further explore including more products in the joint venture’s operations.
In other words, the currently agreed-upon “mutually agreed varieties” are just a starting point. The factory’s production capacity and product lines may expand significantly in the future as the cooperation deepens.
This joint venture is also an important piece of AstraZeneca’s commitment to invest over 100 billion yuan in China by 2030. In January 2026, AstraZeneca announced plans to invest over 100 billion yuan in China by 2030, comprehensively deepening its full value chain layout in R&D, production, commercialization, and ecosystem cooperation. The joint venture signing on August 5th represents a substantial implementation of this 100 billion yuan commitment on the manufacturing side.
From 5.3 billion to 27.6 billion
The relationship between CSPC and AstraZeneca has seen four major collaborations in less than two years. Describing it as a “lightning-fast romance” would be no exaggeration.
First attempt: October 2024, small molecule trial.
This first collaboration between the two companies is a relatively traditional product licensing transaction. AstraZeneca acquired the global exclusive rights to CSPC’s preclinical small molecule drug YS2302018. CSPC received a $100 million upfront payment and is eligible to receive up to $370 million in development milestone payments and up to $1.55 billion in sales milestone payments, with a potential total value of approximately $1.92 billion. This is a typical “product export” deal—CSPC sells a molecule, and AstraZeneca buys a molecule.
The second time: In June 2025, the AI platform will be launched.
This collaboration has been upgraded, no longer focusing on a single product, but leveraging CSPC’s AI drug discovery platform to jointly advance the development of novel oral drug candidates. CSPC received an upfront payment of $110 million, with a potential total value of $5.33 billion. MNCs are starting to pay for Chinese technology platforms—this is a signal.
The third: In January 2026, a record-breaking $18.5 billion deal.
This is the largest licensing deal ever made by a Chinese pharmaceutical company. The two parties signed a research and development collaboration and licensing agreement to jointly develop projects such as the long-acting GLP-1R/GIPR agonist SYH2082. The upfront payment is as high as $1.2 billion, with a potential total transaction value of $18.5 billion. GLP-1 is currently one of the hottest drug markets globally, and AstraZeneca’s willingness to pay such a high price for this asset from CSPC demonstrates that CSPC’s accumulation of expertise in peptide drugs has reached a globally competitive level.
Fourth time: July 2026, small nucleic acid platform output.
Just one month before the joint venture agreement was signed, the two parties deepened their cooperation once again. This time, the collaboration focused on CSPC’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform. The potential total transaction value is $1.77 billion. This marks a shift in the overseas expansion of small Chinese nucleic acid companies, moving from “monetizing individual products” to “outputting platform value.”
The four collaborations totaled a staggering $27.62 billion. The cooperation methods evolved from single-product licensing to AI platform partnerships, to exorbitant GLP-1 transactions, to the export of small nucleic acid platforms, and finally to joint ventures for factory construction—each step representing an upgrade.
On the same day the joint venture agreement was signed, CSPC also received a $10 million milestone payment from AstraZeneca, a result of the AI drug collaboration agreement signed in June 2025.
The signing of the joint venture agreement and the receipt of payment, when put together, send an unmistakable signal: the trust between the two parties has evolved from a “transactional relationship” to a “strategic symbiotic relationship.”
Why now?
To truly understand the significance of the collaboration between CSPC and AstraZeneca, we must place it within a broader context.
First, the “BD Big Bang” of innovative drugs in China.
In 2026, the enthusiasm for licensing Chinese innovative drugs abroad reached an unprecedented level. In the first half of the year, the total value of business development (BD) transactions for Chinese innovative drugs reached US$106.3 billion, approaching the level of the entire year of 2025. In the first quarter of 2026, the total value of cross-border licensing transactions reached US$60 billion, a year-on-year increase of 73%. In 2025, there were 157 overseas licensing transactions for Chinese innovative drugs, totaling approximately US$135.7 billion, a significant leap compared to 94 transactions and US$51.9 billion in 2024.
Multinational pharmaceutical companies are snapping up assets in China. Eli Lilly, Pfizer, AstraZeneca… almost every top-ranked global pharmaceutical giant has established a dedicated business development (BD) team in China to closely monitor the country’s early-stage R&D pipelines.
Secondly, the cooperation model has evolved from “buying and selling” to “symbiosis”.
In the past, the cooperation model between Chinese pharmaceutical companies and multinational corporations (MNCs) was relatively simple: a Chinese company would develop a molecule, sell it to a multinational corporation, receive an initial payment and milestone payments, and the transaction would be completed. This was a “one-off deal.”
But now, the model is changing. Cooperation is shifting from “one-way sales” to “two-way joint research and development and rights exchange”; from “single product transactions” to “comprehensive output of technology platforms, complete solutions, and industrial systems”; and from “product licensing” to “jointly developing multiple early pipelines using their own innovative technology platforms”.
The evolution of the relationship between CSPC and AstraZeneca is almost a textbook example of this evolutionary process. From selling a molecule (2024), to selling an AI platform (2025), to selling the blockbuster asset GLP-1 (January 2026), to selling the siRNA platform (July 2026), and then to the joint venture to build a factory (August 2026) – the depth of cooperation has gradually increased, from “transaction” to “bondage”, from “buying and selling” to “symbiosis”.
Third, MNCs are “early-stage” binding with Chinese innovation.
A noteworthy trend is that MNCs are no longer content with acquiring mature assets that have already entered late-stage clinical trials. They are beginning to extend their reach to earlier stages—preclinical and even target discovery.
The fourth collaboration between CSPC and AstraZeneca (siRNA platform) is a typical example: the two companies will jointly discover and develop preclinical drug candidates with therapeutic potential targeting two targets. This means that the two companies are already working together before the molecules are even formed. What MNCs are paying heavily for is no longer the rights to a single molecule, but rather the “reusable technological capabilities” of Chinese pharmaceutical companies.
This “early binding” strategy serves two purposes: for MNCs, it aims to secure high-quality assets in the fierce global competition for innovative drugs; for Chinese pharmaceutical companies, it leverages MNCs’ global clinical and commercialization capabilities to unlock greater value for their own technology platforms.
Finally, China is becoming a global pharmaceutical “manufacturing hub”.
Another significant aspect of the joint venture lies in manufacturing. AstraZeneca will locate a global biopharmaceutical manufacturing base in Shijiazhuang, reflecting a reassessment of China’s manufacturing capabilities by multinational pharmaceutical companies.
In the past, China’s role in the global pharmaceutical industry chain has been primarily that of a “raw material production base” or a “formulation contract manufacturer.” However, this time, CSPC is exporting its AI-driven GMP production and operation capabilities—an intelligent and digitalized advanced manufacturing capability. In its announcement, CSPC Pharmaceutical Group stated that this collaboration marks a further extension of its internationalization strategy from “exporting products and technologies” to “exporting its production system and supply chain capabilities.”
Against the backdrop of global pharmaceutical companies continuously optimizing their R&D, production, and supply chain layouts, high-quality, efficient, and sustainable production and supply capabilities are increasingly becoming a core competitive advantage in the global innovative drug industry chain. China’s competitiveness in this segment is shifting from “cost advantage” to “technological advantage.”
An upgrade without end
The joint venture agreement signed on August 5 will not be the end of the story between CSPC and AstraZeneca.
From their first handshake in October 2024 to the joint venture factory construction in August 2026, the relationship between the two companies has transformed from “trading counterparties” to “strategic partners” in less than two years. The speed and depth of this transformation are rare in the history of international cooperation in China’s pharmaceutical industry.
Behind this lies CSPC’s continuous investment in innovation and transformation—it has built eight innovative technology platforms covering cutting-edge areas such as small molecules, antibodies, ADCs, and siRNA; its siRNA pipeline has about 10 products under development, with the most advanced having progressed to Phase III clinical trials. These technological assets form the underlying logic for its continued attraction of AstraZeneca’s investment.
Behind this lies AstraZeneca’s long-term commitment to the Chinese market — a 100 billion RMB investment by 2030, encompassing the entire value chain from R&D to production to commercialization. The joint venture is simply the manufacturing manifestation of this commitment.
More importantly, this reflects a systemic upgrade underway across China’s pharmaceutical industry. Collaboration between Chinese innovative drugs and multinational MNCs is entering a new phase of “early-stage partnerships, risk-sharing, and value co-creation.” The cooperation model is shifting from one-way sales to two-way collaborative research, value output is evolving from single-product transactions to platform-based output, and regional positioning is diversifying from single-market to global.
The story of CSPC and AstraZeneca is a story about building trust. It is also a story about the Chinese pharmaceutical industry moving from “following” to “running alongside”.
But the story isn’t over yet. What products will the joint venture produce in the future? In what form will the fifth and sixth collaborations between the two parties take? To what extent will the cooperation model between Chinese innovative drugs and MNCs evolve?
The answers to these questions are being written. The factory in Shijiazhuang has only just driven its first pile.
Source: CSPC Pharma Group & AstraZeneca | Top Image: Photoshop
